Anti-Müllerian hormone kinetics in pregnancy and post-partum: a systematic review

McCredie, Sarah; Ledger, William; Venetis, Christos A.

doi:10.1016/j.rbmo.2017.02.005

Cited by 17 publications

(20 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus, it is plausible that high E 2 levels would not inhibit AMH production in the ovaries of women with PCOS, as they would do in controls, and this could also be the case during pregnancy, again supporting the idea of an existing ovarian activity during pregnancy. On the other hand, peripheral conversion of androgens to estrogens in fat tissue might be more pronounced in women with PCOS also presenting with high AMH levels, and this might explain the correlation (9). In the present study AMH levels correlated negatively with maternal age only in the control group, but not in PCOS, in line with previous data (41).…”

Section: Discussionsupporting

confidence: 91%

“…This also applies to PCOS pregnancies during the second trimester (28) and here at late third trimester, because the women at term presented with two-fold greater AMH levels compared with controls, although the levels were significantly lower than reported in nonpregnant women with PCOS. Indeed, AMH levels have been shown to decrease as gestation advances, and this has been postulated to be a result of suppressed gonadotropin release (33) and inhibition of follicular recruitment due to placental estrogen and P secretion (34), although some follicular recruitment seems to occur even during pregnancy (9). There was overlap in AMH levels between the PCOS and control groups.…”

Section: Discussionmentioning

confidence: 99%

“…Given that in clinical settings AMH correlates well with the ovarian antral follicle count, it has been used as a marker of ovarian follicle reserve and to guide clinical practice, especially in the IVF setting (2,7,8). During pregnancy, levels of circulating AMH decline as a result of ovarian down-regulation and cessation of folliculogenesis brought about by placental steroids, but a rapid postpartum increase can be detected (9). Until recently AMH was considered to be simply a marker of ovarian reserve; however, AMH receptor 2 (AMHR2) expression has been detected in human endometrium and placenta and recently also in GnRH neurons (10)(11)(12).…”

mentioning

confidence: 99%

See 2 more Smart Citations

Circulating antimüllerian hormone and steroid hormone levels remain high in pregnant women with polycystic ovary syndrome at term

Piltonen

Giacobini

Edvinsson

et al. 2019

Fertility and Sterility

View full text Add to dashboard Cite

Objective: To investigate plasma antim€ ullerian hormone (AMH) concentration and its relation to steroid hormone levels in pregnant women with polycystic ovary syndrome (PCOS) and controls at term. Design: Case-control study. Setting: University-affiliated hospital. Patient(s): A total of 74 pregnant women at term: 25 women with PCOS (aged 31.6 AE 3.9 years [mean AE standard deviation], body mass index 24.0 AE 3.9 kg/m2, mean gestational length 279 AE 9 days) and 49 controls (aged 31.7 AE 3.3 years, body mass index 24.0 AE 3.3 kg/m2, mean gestational length 281 AE 9 days). Intervention(s): None. Main Outcome Measure(s): Plasma AMH and steroid hormone levels. Result(s): Antim€ ullerian hormone, T, and androstenedione levels were higher in women with PCOS at term compared with controls, whereas estrogen and P levels were similar. The differences were pronounced in women carrying a female fetus. Testosterone and AMH levels correlated positively in both groups, but E 2 levels only in women with PCOS. Conclusion(s): Pregnant women with PCOS present with elevated AMH and androgen levels even at term, suggesting a hormonal imbalance during PCOS pregnancy. Differences were detected especially in pregnancies with a female fetus, raising the question of whether female pregnancies are more susceptible to AMH and steroid hormone actions.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Circulating antimüllerian hormone and steroid hormone levels remain high in pregnant women with polycystic ovary syndrome at term

Piltonen

Giacobini

Edvinsson

et al. 2019

Fertility and Sterility

View full text Add to dashboard Cite

show abstract

“…Some women had initially low concentrations of AMH that stayed at low levels throughout gestation. A recent review by McCredie et al examined 8 studies of AMH in pregnancy and noted a similar rate of decline during the first trimester . Different mechanisms have been associated with heterogeneity in AMH decline during pregnancy including fetal sex and maternal BMI.…”

Section: Discussionmentioning

confidence: 99%

“…Stojsin‐Carter et al observed in cattle that female cattle pregnant with male fetuses had higher AMH in early pregnancy (days 35‐175) compared with those with female fetuses . Evidence on BMI‐specific effects on AMH decline have been inconclusive with reports from studies suggesting both positive and negative associations between maternal BMI and AMH concentration during gestation . Other mechanisms may explain this observed trend, such as pregnancy‐induced hemodilution with concurrent plasma‐protein binding increase and estrogen‐induced AMH suppression during pregnancy .…”

Section: Discussionmentioning

confidence: 99%

A pilot longitudinal study of anti‐Müllerian hormone levels throughout gestation in low risk pregnancy

Freeman

Whitcomb

Roy

et al. 2018

Health Science Reports

View full text Add to dashboard Cite

Background: Anti-Mϋllerian hormone (AMH) plays an important role regulating ovarian sensitivity to follicle-stimulating hormone and luteinizing hormone in folliculogenesis. Anti-Mϋllerian hormone is well established as a biomarker of ovarian reserve but may also have utility in predicting pregnancy outcomes. Few studies have described AMH levels in pregnancy and, among those that have, most have used cross-sectional study designs and are limited to participants seeking fertility treatment. Our aim was to analyze AMH longitudinally in low-risk pregnancies. Methods:We conducted a prospective cohort study at Baystate Medical Center, a large tertiary care hospital in Springfield, MA, USA. We recruited women (n = 30) with low risk, singleton pregnancies, aged 18 to 35 years, with BMI between 18 and 40 kg/ m 2 , and without preexisting disease. Anti-Mϋllerian hormone (pmol/L) was measured in plasma samples collected at 5 prenatal care visits throughout gestation.Results: Anti-Mϋllerian hormone levels varied significantly over gestation (Friedman's analysis of variance, P value < .0001). At gestational weeks 7 to 10, average AMH was 36.7 pmol/L (standard error = 8.1) and at weeks 34 to 37 was 9.5 pmol/L (standard error = 1.9). Initial AMH varied between women, and an overall significant log-linear decline was observed.Conclusions: Anti-Mϋllerian hormone varies between women and declines exponentially during pregnancy. The biological mechanism of the heterogeneity of AMH decline over gestation is unclear. Future studies evaluating AMH throughout pregnancy that also assess gravid health and pregnancy outcomes are warranted. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

show abstract

Anti-Müllerian hormone levels and risk of type 2 diabetes in women

et al. 2020

View full text Add to dashboard Cite

Aims/hypothesis Given its role in ovarian follicle development, circulating anti-Müllerian hormone (AMH) is considered to be a marker of reproductive ageing. Although accelerated reproductive ageing has been associated with a higher risk of type 2 diabetes, research on the relationship between AMH and type 2 diabetes risk is scarce. Therefore, we aimed to investigate whether age-specific AMH levels and age-related AMH trajectories are associated with type 2 diabetes risk in women. Methods We measured AMH in repeated plasma samples from 3293 female participants (12,460 samples in total), aged 20–59 years at recruitment, from the Doetinchem Cohort Study, a longitudinal study with follow-up visits every 5 years. We calculated age-specific AMH tertiles at baseline to account for the strong AMH–age correlation. Cox proportional hazards models adjusted for confounders were used to assess the association between baseline age-specific AMH tertiles and incident type 2 diabetes. We applied linear mixed models to compare age-related AMH trajectories for women who developed type 2 diabetes with trajectories for women who did not develop diabetes. Results During a median follow-up of 20 years, 163 women developed type 2 diabetes. Lower baseline age-specific AMH levels were associated with a higher type 2 diabetes risk (HRT2vsT3 1.24 [95% CI 0.81, 1.92]; HRT1vsT3 1.62 [95% CI 1.06, 2.48]; ptrend = 0.02). These findings seem to be supported by predicted AMH trajectories, which suggested that plasma AMH levels were lower at younger ages in women who developed type 2 diabetes compared with women who did not. The trajectories also suggested that AMH levels declined at a slower rate in women who developed type 2 diabetes, although differences in trajectories were not statistically significant. Conclusions/interpretation We observed that lower age-specific AMH levels were associated with a higher risk of type 2 diabetes in women. Longitudinal analyses did not show clear evidence of differing AMH trajectories between women who developed type 2 diabetes compared with women who did not, possibly because these analyses were underpowered. Further research is needed to investigate whether AMH is part of the biological mechanism explaining the association between reproductive ageing and type 2 diabetes.

show abstract

Anti-Müllerian hormone kinetics in pregnancy and post-partum: a systematic review

Cited by 17 publications

References 37 publications

Circulating antimüllerian hormone and steroid hormone levels remain high in pregnant women with polycystic ovary syndrome at term

Circulating antimüllerian hormone and steroid hormone levels remain high in pregnant women with polycystic ovary syndrome at term

A pilot longitudinal study of anti‐Müllerian hormone levels throughout gestation in low risk pregnancy

Anti-Müllerian hormone levels and risk of type 2 diabetes in women

Contact Info

Product

Resources

About